Overview A Study of Bermekimab (JNJ-77474462) in the Treatment of Participants With Moderate to Severe Atopic Dermatitis Status: Recruiting Trial end date: 2022-08-29 Target enrollment: Participant gender: Summary The purpose of this study is to evaluate the efficacy and safety of bermekimab in participants with moderate to severe atopic dermatitis (AD). Phase: Phase 2 Details Lead Sponsor: Janssen Research & Development, LLC